Business Wire

Dole Announces its Promises, Bringing Interdependent Prosperity to People and the Planet

30.6.2020 10:00:00 EEST | Business Wire | Press release

Share

Dole Packaged Foods and Dole Asia Fresh, divisions of Dole Asia Holdings Pte. Ltd.. announced today “The Dole Promise,” which aims to increase access to sustainable nutrition, decrease food waste, plastics in packaging and carbon emissions and grow value for the company’s stakeholders, including farmers and shareholders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005347/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Dole Promise, inspired by Japanese philosophy, Sampo Yoshi. (Graphic: Business Wire)

“The Dole Promise reflects the recognition that 'business as usual' is unacceptable in the face of a looming food crisis and the growing expectations of the next generation," said Pier Luigi Sigismondi, President of Dole Packaged Foods. “The impacts of the COVID-19 global pandemic could see 265 million additional people pushed to the brink of starvation by the end of this year,1 double the numbers of last year. At the same time, the challenges of climate change, resource waste and declining natural resources still must be addressed. We believe it is time for a change, and we are taking action where we can be most effective – within our own business.”

The promise draws on the spirit of ‘Sampo Yoshi,’ an 18th century Japanese philosophy that views the well-being of society and business as interdependent, and ensures the business is beneficial to the seller, to the buyer and to the community.

“The triple-win concept of ‘Sampo Yoshi’ has been part of Japanese culture for centuries, and is now at the heart of The Dole Promise as we play our part in helping to restore balance in the world by doubling down on our mission to put the health of the planet at the heart of everything we do,” said Richard Toman, President Dole Asia Fresh Division. “It’s a promise that Dole is making to do business differently, and to join forces with those who are equally committed to bringing back the goodness of the earth.”

The Dole Promise frames this philosophy to include:

Better for People:

  • Access to sustainable nutrition for 1 billion people by 2025
  • Moving towards zero processed sugar in all Dole products by 2025

Better for Planet:

  • Moving towards zero fruit loss from Dole farms to markets by 2025
  • Moving towards zero fossil-based plastic packaging by 2025
  • Aiming for net zero carbon emissions in Dole operations by 2030

Better for all Stakeholders:

  • Dole will continue to positively impact all farmers, communities and people working for Dole – through its commitment to equal opportunity, living wages, and an ever-increasing level of safety, nutrition, and wellbeing. The company also seeks to advance human rights within the direct operations and supply chains by building a culture of transparency and accountability. The company also aims for a 50% increase in the value of its business by 2025.

The growing problem of food inequality, which existed before the pandemic, has now reached crisis proportions and needs a collective effort to address. Dole’s commitment to increase access to sustainable nutrition will play a role, along with its effort to eliminate food waste.

“Our promise is not just about improving our world today,” said Sigismondi. "We have a responsibility to future generations to work towards a more equitable and sustainable future.”

The launch video, “Dear Leaders of the World,” gives voice to the concern of today’s youth about their generation’s future if something doesn’t change now.

“The next generation is right to question why we have left problems like climate change for so long. There are inter-generational repercussions. That is why we are increasing our efforts in key areas like reducing carbon emissions and working towards removing plastic packaging from our supply chain. Our promise puts the heart of the planet and people at the center of everything we do,” added Sigismondi.

Elevating the end-to-end value chain

Addressing the many gaps in access to good nutrition and reduction of waste cannot be done alone. Dole is partnering with Solidaridad; an international civil society organization with over fifty years of experience in creating fair and sustainable supply chains from producer to consumer across five continents. They are developing innovative solutions for healthy and sustainable food systems ensuring that farmers and workers have a living income, influence over their destiny, and can produce in balance with nature. Dole is also enlisting the help of Forum for the Future, an organisation that works in partnership with business, governments and civil society to accelerate the shift toward a sustainable future, Future Food Institute a center of excellence for food intelligence and the food innovation ecosystem and Rocana, a venture capital firm focused on clean and functional nutrition.

Later this year, Dole is launching the Sunshine for All™ Investment Fund to support additional strategic partnerships and strategic investments in these areas around the world. The US$2 million annual fund will work with innovators, start-ups and progressive partners to help deliver on the Dole Promise in key areas such as nutrition products, materiality, advisory and implementation of crucial practices to help achieve the ambitions that have been set.

Additionally, Dole is bringing these commitments inside their company walls, with employee programs that educate and encourage all Dole employees to live “The Dole Promise.”

To see the full details of the Dole Promise and the Sunshine for All investment fund visit sunshineforall.com and download the Dole Promise visual here .

Dole Asia Holdings Pte. Ltd.

Dole Asia Holdings Pte. Ltd., is a worldwide leader and innovator in the production and marketing of high-quality packaged fruit and healthy snacks. Dole Asia Holdings is also one of Asia's largest producers and marketers of high-quality fresh fruits and vegetables. For more information please visit dolesunshine.com or doleintlcsr.com. The Dole Promises are from the Dole Asia Holdings group of companies, and apply to their products, which can be seen at sunshineforall.com

1 https://www.mercycorps.org/blog/quick-facts-global-hunger#global-hunger

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:
Brittney Theriault
btheriault@golin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye